EE390 Optimizing the Use of Risk Factors to Guide the Cost-Effective Use of Palivizumab Prophylaxis Against Severe Respiratory Syncytial Virus Infection in Korean Infants Born 32–35 Weeks’ Gestational Age
Abstract
Authors
I. Keary J.M. Kang B. Paes B. Rodgers-Gray J. Fullarton J.E. Tarride H.J. Yang Y.S. Chang X. Carbonell-Estrany